查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
临床试验中的区块链市场－2023年至2028年预测
市场调查报告书
商品编码
1410138

临床试验中的区块链市场－2023年至2028年预测

Blockchain In Clinical Trials Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年区块链临床试验市场规模预计为103,054,000美元

在医疗保健和製药业，临床试验的区块链市场正在成为游戏规则的改变者。这种新颖的策略有望透过利用区块链技术的去中心化和不可逆性来提高临床试验过程的开放性、安全性和效率。区块链提供了一种分散式帐本技术，允许相关人员之间即时交换和检验临床实验资料，同时保持资料完整性。区块链透过简化资料管理、身份验证和同意程序来减少资料操纵的威胁并确保监管合规性。这项技术增强了参与者的信心，缩短了试验时间，降低了成本，并彻底改变了临床试验。随着对课责和资料的需求不断增长，临床试验中的区块链市场有望彻底改变药物研究并推动患者照护领域的突破。

提高资料透明度和完整性将推动临床试验中区块链市场的成长

提高资料透明度和完整性是临床试验市场区块链的关键成长动力。区块链的去中心化和不可变的帐本​​架构使临床试验资料可见、可追溯、防篡改。研究人员、监管机构和患者都可以安全地即时存取和检验资料，从而促进信任和协作。这种透明度的提高有助于及早检测和解决资料异常，确保测试结果的准确性和可靠性。此外，消除集中式资料孤岛可以降低资料篡改和未授权存取的风险，从而提高资料完整性。随着临床试验对强大资料管理和信任的要求不断提高，区块链技术的普及程度也不断提高，推动市场成长。

简化临床试验区块链市场中的资料管理和共用

临床试验中区块链市场的一个显着成长因素是简化资料管理和共用。区块链的分散式帐本技术以安全且高效的方式简化了各个相关人员之间的资料储存、组织和共用。向研究人员、医疗保健提供者和监管机构提供临床实验进展、患者资料和结果的即时更新，从而实现无缝协作和决策。资料可以即时上传、更新和审核，消除了手动记录保存和不必要的资料输入。区块链技术透过打破资料孤岛和维护资料、缩短临床试验期限并提高整体药物开发和患者照护效率来改善整体资料管理流程。

诈欺和资料篡改的减少将推动临床试验中的区块链市场规模。

减少诈欺和资料篡改是临床试验市场区块链的关键成长要素。区块链的去中心化和不可变性确保资料一旦记录就无法编辑或删除，从而消除了资料篡改或未授权存取的风险。区块链上的每笔交易都安全地连接到先前的条目，从而形成透明且审核的资料追踪。资料品质和开放性的提高减少了诈欺并保护敏感的患者资讯。区块链技术可以透过培养患者、研究人员和监管机构等相关人员之间的信任，减少资料操纵的可能性并确保临床试验结果的准确性，从而帮助推动临床试验的这种转变，从而导致技术的广泛采用。

北美是临床试验区块链市场的市场领导者

北美是临床试验区块链的市场领导者。该地区的受欢迎程度可能与其完善的医疗保健基础设施、对研发的重视以及大量重要製药和生物技术公司的存在有关。此外，北美在采用区块链等最尖端科技并将其整合到医疗保健系统方面处于领先地位。该地区有利的法律规范以及研究机构和技术供应商之间的合作伙伴关係推动了区块链在临床试验中的使用。然而，临床试验市场区块链顶级区域的市场动态可能正在改变。

增加临床试验中区块链市场的病患招募与参与度

病患招募和参与是临床试验市场区块链的关键成长动力。区块链技术使个人能够更好地控制自己的健康资料，并允许他们直接参与临床研究。患者可以安全地与研究人员交换健康资讯并同意参加试验，从而改善招募。此外，区块链的开放和去中心化性质可以确保患者能够清楚地看到他们的资料将如何使用，从而提高患者的信任，从而保障资料保护。透过加强患者参与和赋权，临床试验现在可以接触到更广泛的不同参与者，从而产生更具代表性和稳健的研究结果，并最终治疗方法，并促进治疗方法的改进。

公司产品

  • 区块链基础设施解决方案英特尔为区块链网路的开发和部署提供硬体和软体解决方案。这些基础设施解决方案旨在提高临床试验区块链系统的效能、安全性和可扩展性。
  • AccenturemyConcerto(TM)：由Accenture开发的 myConcerto(TM) 是一个基于区块链的平台，旨在提高临床试验的效率和透明度。该技术使相关人员能够安全、即时地共用资料，从而增强协作和决策。
  • IBM 临床开发： IBM 临床开发平台结合了区块链技术来加速临床试验资料管理，由 IBM Watson Health 提供。该平台实现了包括研究人员、赞助商和监管机构在内的相关人员之间安全、透明的资料交换。
  • Medidata Rave Clinical Cloud： Medidata Rave Clinical Cloud 是一个完整的云端基础的平台，利用区块链技术进行资料管理和安全。该平台能够安全、防篡改地收集、处理和储存临床试验资料。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 资讯来源
  • 研究设计

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 业内竞争对手之间的对抗关係
  • 产业价值链分析

第五章临床试验中的区块链市场：按区块链类型

  • 介绍
  • 公共区块链
  • 私有区块链
  • 联盟链
  • 混合区块链

第六章临床试验中的区块链市场：依应用分类

  • 介绍
  • 病患资料管理
  • 供应链管理
  • 临床资料交换与共用
  • 临床试验记录管理
  • 管理知情同意
  • 药品可追溯性和真实性
  • 其他的

第七章临床试验中的区块链市场：按最终用户划分

  • 介绍
  • 製药公司
  • 委託研究组织（CROS）
  • 研究机构和学术中心
  • 医疗服务提供方
  • 其他的
  • 临床试验市场中的区块链：按地区
  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 台湾
    • 其他的

第八章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第九章 公司简介

  • IBM CORPORATION
  • MICROSOFT CORPORATION
  • ORACLE CORPORATION
  • ACCENTURE PLC
  • MEDIDATA SOLUTIONS, INC.（NOW PART OF DASSAULT SYSTEMES）
  • CONSENSYS HEALTH
  • PFIZER INC.
  • ENCRYPGEN, INC.
  • BITFURY GROUP LIMITED
  • GUARDTIME AS
简介目录
Product Code: KSI061615808

The blockchain in clinical trials market was valued at US$103.054 million in 2021.

In the healthcare and pharmaceutical industries, the blockchain in clinical trials market has emerged as a transformational force. This novel strategy promises to improve openness, security, and efficiency in the clinical trial process by leveraging blockchain technology's decentralised and irreversible nature. Blockchain provides a distributed ledger technology that allows for the real-time exchange and verification of trial data across stakeholders while maintaining data integrity. Blockchain reduces data manipulation threats and assures regulatory compliance by streamlining data management, authentication, and consent procedures. This technology increases participant trust, shortens trial times, and lowers costs, revolutionising how clinical trials are done. As the desire for more accountability and data integrity develops, blockchain in clinical trials market is poised to revolutionise drug research and push patient care breakthroughs.

Improved Data Transparency and Integrity Enhances the Blockchain in Clinical Trials Market Growth.

Improved data transparency and integrity are critical growth drivers in the blockchain in clinical trials market. Clinical trial data becomes visible, traceable, and tamper-proof thanks to blockchain's decentralised and immutable ledger architecture. Researchers, regulators, and patients may all safely access and verify data in real-time, encouraging confidence and collaboration. This increased transparency aids in the early detection and resolution of data anomalies, assuring the accuracy and dependability of trial outcomes. Furthermore, removing centralised data silos reduces the danger of data modification and unauthorised access, hence improving data integrity. As the requirement for robust data management and trust in clinical trials grows, so does the popularity of blockchain technology, driving market growth.

Streamlined Data Management and Sharing in Blockchain in Clinical Trials Market.

A prominent growth element in the blockchain in clinical trials market is streamlined data management and sharing. The distributed ledger technology of blockchain streamlines data storage, organisation, and sharing among various stakeholders in a safe and efficient manner. Real-time updates on trial progress, patient data, and outcomes are available to researchers, healthcare providers, and regulators, allowing for seamless cooperation and decision-making. Data may be uploaded, updated, and audited in real-time, eliminating the need for manual record-keeping and unnecessary data entry. Blockchain technology improves the whole data management process by removing data silos and maintaining data integrity, shortening clinical trial deadlines and improving overall drug development and patient care efficiency.

Reduction in Fraud and Data Manipulation Boosts the Blockchain in Clinical Trials Market Size.

Reduced fraud and data tampering are critical growth drivers in the blockchain in clinical trials market. The decentralised and unchangeable nature of blockchain assures that data cannot be edited or erased once recorded, removing the danger of data tampering and unauthorised access. Each transaction on the blockchain is securely connected to prior entries, resulting in a data trail that is transparent and auditable. This improved data quality and openness discourages fraudulent practises and safeguards sensitive patient information. Blockchain technology fosters trust among stakeholders, including patients, researchers, and regulatory authorities, by reducing the possibility of data manipulation and ensuring the accuracy of clinical trial results, resulting in widespread adoption of this transformative technology in clinical trials.

North America is the Market Leader in the Blockchain in Clinical Trials Market.

North America was regarded as the market leader in the blockchain in clinical trials market. The popularity of this region may be linked to its well-established healthcare infrastructure, a strong emphasis on R&D, and the presence of numerous important pharmaceutical and biotechnology businesses. Furthermore, North America has been in the forefront of adopting and integrating cutting-edge technology such as blockchain into healthcare systems. The region's favourable regulatory framework, as well as alliances between research institutes and technology suppliers, have advanced the use of blockchain in clinical trials. However, market dynamics may have changed, in the top region in the blockchain in clinical trials market.

Increased Patient Recruitment and Engagement in Blockchain in Clinical Trials Market.

Patient recruitment and engagement are important growth drivers in the blockchain in clinical trials market. Blockchain technology gives individuals more control over their health data and allows them to participate directly in clinical studies. Patients may safely exchange their health information with researchers and consent to participate in trials, which improves recruitment. Furthermore, the open and decentralised nature of blockchain increases patient confidence by offering a clear knowledge of how their data will be utilised and protecting data protection. Clinical trials can access a broader pool of varied participants with enhanced patient participation and empowerment, resulting in more representative and robust research outputs, eventually promoting improvements in medical treatments and cures.

Key Developments:

  • In May 2023, Medidata, a Dassault Systemes business, is expanding its Patient Insights Programme through a collaboration with Canary Advisors, a consulting firm specialising in patient-centred medication and device development. The Patient Insights Programme at Medidata incorporates a patient-centred approach into the design and development of clinical trial protocols and technology. Medidata creates unique workshops to assist the development of patient-facing solutions to enhance clinical trial experiences, accelerate clinical trial delivery times, and bring treatments to market more quickly.
  • In June 2023, IBM announced a $4.6 billion purchase deal with Vista Equity Partners for Apptio Inc., a pioneer in financial and operational IT management and optimization (FinOps) software. Apptio's purchase will accelerate IBM's IT automation capabilities and empower company executives to achieve greater business value from technology investments.
  • In July 2023, Bira 91, an Indian premium beer brand with operations in 24 countries, is engaging with Accenture on an enterprise reinvention programme to boost growth, enhance business agility, and accelerate innovation. Accenture will assist Bira 91 in designing and deploying a digital core, which incorporates data, artificial intelligence, and machine learning, using SAP S/4HANA to allow a holistic reinvention of its organisation through the convergence of different technological platforms, as part of its transformation plan. The scalable technological platform, which is cloud-based, will boost data visibility and accessibility across the organisation, assisting in decision-making and increasing productivity.

Company Products:

  • Blockchain Infrastructure Solutions: Intel supplied hardware and software solutions for the development and deployment of blockchain networks. These infrastructure solutions sought to improve the performance, security, and scalability of clinical trial blockchain systems.
  • Accenture myConcerto™: Accenture developed myConcerto™, a blockchain-enabled platform meant to improve clinical trial efficiency and transparency. The technology enabled stakeholders to share data in a safe and real-time manner, increasing cooperation and decision-making.
  • IBM Clinical Development: The IBM Clinical Development platform, which combined blockchain technology to accelerate clinical trial data administration, was delivered by IBM Watson Health. The platform enabled secure and transparent data exchange among many parties, including researchers, sponsors, and regulatory bodies.
  • Medidata Rave Clinical Cloud: Medidata Rave Clinical Cloud was a complete cloud-based platform that utilised blockchain technology for data management and security. The platform permitted the safe and tamper-proof gathering, processing, and storage of clinical trial data.

Segmentation:

By Type Of Blockchain

  • Public Blockchain
  • Private Blockchain
  • Consortium Blockchain
  • Hybrid Blockchain

By Application

  • Patient Data Management
  • Supply Chain Management
  • Clinical Data Exchange And Sharing
  • Clinical Trial Recordkeeping
  • Informed Consent Management
  • Drug Traceability And Authenticity
  • Others

By End-User

  • Pharmaceutical Companies
  • Contract Research Organizations (Cros)
  • Research Institutes And Academic Centers
  • Healthcare Providers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Sources
  • 2.3. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY TYPE OF BLOCKCHAIN

  • 5.1. Introduction
  • 5.2. PUBLIC BLOCKCHAIN
  • 5.3. PRIVATE BLOCKCHAIN
  • 5.4. CONSORTIUM BLOCKCHAIN
  • 5.5. HYBRID BLOCKCHAIN

6. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. PATIENT DATA MANAGEMENT
  • 6.3. SUPPLY CHAIN MANAGEMENT
  • 6.4. CLINICAL DATA EXCHANGE AND SHARING
  • 6.5. CLINICAL TRIAL RECORDKEEPING
  • 6.6. INFORMED CONSENT MANAGEMENT
  • 6.7. DRUG TRACEABILITY AND AUTHENTICITY
  • 6.8. OTHERS

7. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. PHARMACEUTICAL COMPANIES
  • 7.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 7.4. RESEARCH INSTITUTES AND ACADEMIC CENTERS
  • 7.5. HEALTHCARE PROVIDERS
  • 7.6. OTHERS
  • 7.7. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY GEOGRAPHY
  • 7.8. Introduction
  • 7.9. North America
    • 7.9.1. United States
    • 7.9.2. Canada
    • 7.9.3. Mexico
  • 7.10. South America
    • 7.10.1. Brazil
    • 7.10.2. Argentina
    • 7.10.3. Others
  • 7.11. Europe
    • 7.11.1. United Kingdom
    • 7.11.2. Germany
    • 7.11.3. France
    • 7.11.4. Italy
    • 7.11.5. Spain
    • 7.11.6. Others
  • 7.12. Middle East and Africa
    • 7.12.1. Saudi Arabia
    • 7.12.2. UAE
    • 7.12.3. Others
  • 7.13. Asia Pacific
    • 7.13.1. Japan
    • 7.13.2. China
    • 7.13.3. India
    • 7.13.4. South Korea
    • 7.13.5. Indonesia
    • 7.13.6. Taiwan
    • 7.13.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. IBM CORPORATION
  • 9.2. MICROSOFT CORPORATION
  • 9.3. ORACLE CORPORATION
  • 9.4. ACCENTURE PLC
  • 9.5. MEDIDATA SOLUTIONS, INC. (NOW PART OF DASSAULT SYSTEMES)
  • 9.6. CONSENSYS HEALTH
  • 9.7. PFIZER INC.
  • 9.8. ENCRYPGEN, INC.
  • 9.9. BITFURY GROUP LIMITED
  • 9.10. GUARDTIME AS